Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Investor Presentation (June 2020)
17 slides from Emvision Medical Devices's investor presentation, Jun 25, 2020
Slide 1: Investor Presentation
For personal use only www.emvision.com.au INVESTOR PRESENTATION
Slide 2: Breakthrough Technology
BREAKTHROUGH For personal use only TECHNOLOGY Commercialising novel electromagnetic imaging technology as a result of 10 TRANSFORMATIVE years development at University of Queensland POINT-OF-CARE IMAGING SOLVING UNMET CLINICAL NEEDS Rapidly Diagnose & Monitor Stroke Immense commercial opportunity in
Slide 3: What Problems Are We Solving?
For personal use only WHAT PROBLEMS ARE WE SOLVING? HEALTH & ECONOMIC BURDEN EFFECTIVE TREATMENTS UNDER DEPLOYED LACK OF PORTABLE IMAGING Recent years have seen ground-breaking stroke Imaging is a prerequisite to determine the type therapies implemented – including innovative of stroke, the appropri
Slide 4: The Stroke Care Opportunity
THE STROKE CARE OPPORTUNITY For personal use only Stroke Onset 15 mins to 2.5 hours < 2.5 hours < 3 hours < 24 hours <24 hours - 3 weeks <3 weeks - 3 years+ TYPICAL Pre-hospital Triage Hospital ED Image Studies Treatment Plan In-Ward Stroke Care Rehabilitation PATIENT Paramedics Patient arrives at C
Slide 5: Technology Overview
TECHNOLOGY OVERVIEW For personal use only SHARED UNDERLYING PRINCIPLES NON-DESTRUCTIVE TESTING Array of antennas send pulses of low-power 1 electromagnetic waves into the head Microwave frequency 2 – 18 GHz SECURITY Millimeter frequency Waves penetrate tissue in a non-ionizing and 10 - 80 GHz 2 harm
Slide 6: Promising Preliminary Clinical Prototype Images
PROMISING PRELIMINARY For personal use only CLINICAL PROTOTYPE IMAGES Detected Abnormal Tissue Commenced 30 patient pilot-clinical trial at the Princess Alexandra Hospital in Brisbane in late January 2020 to: Provided a good guide to the extent of brain tissue damaged or under threat 1 Collect data
Slide 7: Patient A
PATIENT A Right M2 Occlusion For personal use only GROUND TRUTH EMVISION SCANS OVERLAID EMVISION SCANS (MULTIPLE ALGORITHMS) GROUND TRUTH MRI L R L R L R Beamforming Direct Mapping Beamforming Direct Mapping L R Perfusion CT / MRI L R L R Statistical Tomography Statistical Fusion with Fusion www.emv
Slide 8: Patient B
PATIENT B Left frontal small stroke, difficult to see clot and probably small M3 occlusion. Posterior CTP change probably fragmented clot For personal use only GROUND TRUTH EMVISION SCANS OVERLAID EMVISION SCANS (MULTIPLE ALGORITHMS) GROUND TRUTH MRI L R L R L R Beamforming Direct Mapping Beamformin
Slide 9: Clinical Feedback
CLINICAL FEEDBACK For personal use only PROF MICHAEL O’SULLIVAN A/PROF DAVID COOK Neurologist specializing in Stroke Lead Investigator, Snr Critical Care Specialist EMV Clinical Advisor EMV Clinical Advisor “Although obviously preliminary, these early “The last two years has seen EMVision technology
Slide 10: Product Development Roadmap
PRODUCT DEVELOPMENT ROADMAP For personal use only 2019 2020-21 CLINICAL PROTOTYPE 1 st GEN FOR COMMERCIALISATION FIRST RESPONDER Clinical prototype to gather data For use in ICUs, stroke and neurology Next generation device that from stroke patients to enable wards. This device intends to offer a in
Slide 11: Road to Commercialisation
ROAD TO COMMERCIALISATION For personal use only CY Q3 2020 Q4 2020 2021 Pilot-Clinical Trial Results from Pivotal Clinical Pivotal Clinical Trial Pivotal Clinical CLINICAL TRIALS Completion Pilot Clinical Trial Trial Site Selection Ethics Approval Trial Enrolment 1 st GEN DEVICE DEVELOPMENT Refineme
Slide 12: Key Addressable Markets
KEY ADDRESSABLE MARKETS For personal use only US. GERMANY FRANCE UK. JAPAN AU. CAPITAL E QUIPME N T PRICIN G TARGE T ULTRASOUND STROKE LOW RANGE ~$20,000 USD 2,200 450 140 150 625 105 / NEUROLOGY WARDS TARGETING MID RANGE CRITICAL CARE UNITS 2,800 1,700 600 210 650 150 ULTRASOUND PRICING ULTRASOUND
Slide 13: Attractive Revenue Model
ATTRACTIVE REVENUE MODEL For personal use only SALES MODEL: DISTRIBUTION OR DIRECT MULTIPLE RECURRING REVENUE STREAMS OVER LIFE OF EACH DEVICE Distribution Partners EMVision’s sales model will be flexible on a FREQUENCY:HIGH geography by geography basis. Future distribution $10 partners would purcha
Slide 14: Partners & Collaborators
PARTNERS & COLLABORATORS For personal use only GE Healthcare is the $19 billion healthcare Awarded EMVision a $2.6M CRC-P non-dilutive Developer of EMVision’s IP, CRC-P partner, and business of GE (NYSE:GE) and a leading global cash grant, over three years, in Dec’17. Australia's most successful com
Slide 15: Team
TEAM Significant experience developing and commercialising medical devices For personal use only Dr Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller CEO & Managing Director Chairman Executive Director Co-Inventor & Clinical Advisory Chair Product Design & Development Former
Slide 16: Capital Structure
CAPITAL STRUCTURE For personal use only Shares on issue 63.7m $4.5M PLACE ME N T Total Options on issue 1 8.9m PROMISIN G STROKE IMAGE S Performance Rights2 6m CLIN ICAL PROTOTYPE BUILT Market Cap @ $1.26c* $80m POSITIVE HHT JOIN STROKE ALLIAN CE EV @ $1.26c* $74m TRIAL STARTS IPO Current Cash Balan
Slide 17: Get in Touch
For personal use only www.emvision.com.au GET IN TOUCH Dr Ron Weinberger Scott Kirkland CEO and MD, EMVision Executive Director, EMVision E: rweinberger@emvision.com.au E: skirkland@emvision.com.au P: 02 8667 5337 P: 02 8667 5337
EMVision Medical Devices — Investor Presentation (June 2020) on 6ix